Filing Flows

Filing Flows › Lemaitre Vascular (LMAT) › Stock forecast & fair value

Lemaitre Vascular (LMAT) stock forecast and fair value

Lemaitre Vascular (LMAT) trades at $80.82. 7 analysts' median price target is $100.00 (+24%), from $81.00 to $132.00. Across 27 valuation methods the middle fair value is $61.97 (-23%); the DCF says $70.83.

Price$80.82
Median target$100.00
Fair value, middle$61.97
DCF$70.83
EPS beat rate60%
Lemaitre Vascular fair value by method (price $80.82)Lemaitre Vascular fair value by method (price $80.82)low – highpoint estimateRegime-switching Monte Carlo 10th–9…$76.32DCF — Monte Carlo 10th–90th percent…$70.83P/E vs peers$91.41P/E vs peers, weighted$95.59P/E vs peers, matched$83.68EV/EBITDA vs peers$89.10EV/EBITDA vs peers, weighted$81.27EV/EBITDA vs peers, matched$82.86EV/Sales vs peers$50.76EV/Sales vs peers, weighted$58.38

Fair value by method

MethodLowPointHighvs price
Regime-switching Monte Carlo 10th–90th$49.98$76.32$136.60-6%
DCF — Monte Carlo 10th–90th percentile$55.34$70.83$91.21-12%
P/E vs peers$69.47$91.41$151.68+13%
P/E vs peers, weighted$73.41$95.59$154.99+18%
P/E vs peers, matched$61.97$83.68$130.64+4%
EV/EBITDA vs peers$72.84$89.10$116.77+10%
EV/EBITDA vs peers, weighted$69.70$81.27$89.48+0.6%
EV/EBITDA vs peers, matched$70.42$82.86$106.01+3%
EV/Sales vs peers$39.36$50.76$72.51-37%
EV/Sales vs peers, weighted$43.31$58.38$82.93-28%

Lemaitre Vascular's latest quarter

Lemaitre Vascular, Q3 2026: revenue $68.0M (+11% year over year), operating margin 26.0%, net earnings $15.0M, operating cash flow $22.0M. The chart follows the revenue to costs, profit and cash.

Questions

What is the price target for LMAT stock?

The median of 7 analysts' 12-month targets is $100.00, +24% from $80.82; the range is $81.00 to $132.00. The average rating is buy.

What is Lemaitre Vascular's fair value?

The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $10.93 and $107.00, with a middle value of $61.97 against a price of $80.82. Each method's assumptions are on the page.

Does Lemaitre Vascular usually beat earnings estimates?

It beat the consensus EPS estimate in 60% of the quarters on record.

Is LMAT stock a buy?

Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.